Updated October 16, 2026 with prices and facts re-checked October 14, 2026.
GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
By Novo NordiskUpdated October 16, 2026
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026
Semaglutide overview
GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
Semaglutide at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Pivotal trials
STEP-1 (NEJM 2021, PMID 33567185) — 14.9% mean weight loss at 2.4 mg / 68 weeks
SELECT (NEJM 2023, PMID 37952131) — 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD
FLOW (NEJM 2024, PMID 38785189) — 24% reduction in major kidney/CV events in T2D + CKD
SURPASS-2 (NEJM 2021, PMID 34170647) — head-to-head: tirzepatide produced more weight loss than semaglutide 1 mg (−11.2 kg vs −5.7 kg at the 15 mg dose)
How does the Wegovy titration schedule reach the 2.4 mg dose?
Wegovy steps up weekly doses from 0.25 to 0.5, 1.0, 1.7 and then 2.4 mg, with about four weeks at each step. That means reaching the 2.4 mg maintenance dose typically takes around 16 weeks.
What boxed warning does semaglutide carry?
Semaglutide carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies. Your prescriber reviews this warning with you before starting treatment with any semaglutide brand.
Does NexLife’s compounded semaglutide price rise as the dose increases?
No. NexLife charges the same price at every dose: $139 month to month, or $132, $125 and $119 a month on 3-, 6- and 12-month plans, all charged monthly with no membership (read October 14, 2026).
Which semaglutide brand is approved for weight management rather than diabetes?
Wegovy is the semaglutide brand for chronic weight management and cardiovascular risk reduction; Ozempic and Rybelsus (oral) are for type 2 diabetes. All are made by Novo Nordisk. Compounded semaglutide is not FDA-approved.